Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02596477 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Vepoloxamer in Chronic Heart Failure
A Phase 2 study, sponsored by Mast Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02596477 is a Phase 2 study that was terminated before completion, run by Mast Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT02596477, a Phase 2 study, was terminated before completion, sponsored by Mast Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether vepoloxamer can provide a blood chemical marker and functional benefit to damaged heart muscle cells. This will be evaluated by measurement of blood-based laboratory markers, exercise tolerance, and echocardiograms. In addition, the safety and blood levels of vepoloxamer in subjects with chronic heart failure will be evaluated.
Interventions
- DRUG Vepoloxamer
- OTHER 5% dextrose in water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02596477
The ClinicalTrials.gov registry entry for NCT02596477 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mast Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vepoloxamer is the first listed.
NCT02596477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02596477 about?
NCT02596477 is a clinical study titled "Evaluation of Vepoloxamer in Chronic Heart Failure". The purpose of this study is to evaluate whether vepoloxamer can provide a blood chemical marker and functional benefit to damaged heart muscle cells. This will be evaluated by measurement of blood-based laboratory markers, exercise tolerance, and echocardiograms. In addition, the safety and blood l...
What is the current status of trial NCT02596477?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-10.
What interventions are being tested in trial NCT02596477?
The interventions under investigation include: Vepoloxamer (DRUG), 5% dextrose in water (OTHER).
Who is sponsoring clinical trial NCT02596477?
This trial is sponsored by Mast Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.